Evidence map›Paper›PMID 41490186›Full record

ArticleJournal of visualized experiments : JoVE2025

The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo.

Mozammel Bhuiyan, Michelle Lin, Carly McCurry, Jessica Lamb, Marcio A Diniz, Karni Bedirian, Anil Chauhan, Abhishek Jha, Aditi Jain, Enrique Leira and 10 more

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mozammel BhuiyanDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine of USC; mbhuiyan@usc.edu.
Michelle LinDepartment of Neurosurgery, Keck School of Medicine of USC.
Carly McCurryDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine of USC.
Jessica LambDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine of USC.
Marcio A DinizDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai.
Karni BedirianDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai.
Anil ChauhanDepartment of Internal Medicine, Division of Hematology, Oncology and Blood & Marrow Transplantation, Carver College of Medicine, University of Iowa.
Abhishek JhaDepartment of Internal Medicine, Division of Hematology, Oncology and Blood & Marrow Transplantation, Carver College of Medicine, University of Iowa.
Aditi JainDepartment of Internal Medicine, Division of Hematology, Oncology and Blood & Marrow Transplantation, Carver College of Medicine, University of Iowa.
Enrique LeiraDepartments of Neurology & Neurosurgery, Carver College of Medicine, Department of Epidemiology, College of Public Health, University of Iowa.
Mohammad B KhanThe Medical College of Georgia at Augusta University.
Pradip K KamatThe Medical College of Georgia at Augusta University.
David C HessThe Medical College of Georgia at Augusta University.
Huaxin ShengDepartment of Anesthesiology, Duke University.
Bingren HuUniversity of California, San Diego.
Lauren H SansingDepartment of Neurology, Yale University.
Cenk AyataNeurovascular Research Unit, Massachusetts General Hospital.
Takahiko ImaiNeurovascular Research Unit, Massachusetts General Hospital.
Kirsten LynchLaboratory of NeuroImaging, USC Mark and Mary Stevens Neuroimaging and Informatics Institute of the Keck School of Medicine of USC.
Patrick LydenDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine of USC; Department of Neurology, Keck School of Medicine of USC; plyden@usc.edu.

Funding

The NIH SPAN Coordinating CenterU24NS130600 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LYDEN, PATRICK D · 2023 to 2025
$2.8M
The NIH SPAN Coordinating CenterU24NS113452 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LYDEN, PATRICK D · 2019 to 2021
$2.4M
Y-SPAN: Yale Translational Cerebroprotection Program in SPANU01NS130585 · NINDS · YALE UNIVERSITY · PI SANSING, LAUREN H · 2023 to 2025
$1.9M
Stroke Preclicinal Assessment NetworkU01NS130588 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AYATA, CENK · 2023 to 2025
$1.9M
Testing Cerebroprotective Interventions with Rodent Ischemic Stroke ModelsU01NS130557 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HU, BINGREN · 2023 to 2025
$1.8M
Dysfunctional organelle-specific autophagy leads to brain ischemia-reperfusion injuryR01NS134895 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bingren Hu · 2024 to 2026
$1.8M
Augusta SPAN 2U01NS130590 · NINDS · AUGUSTA UNIVERSITY · PI DHANDAPANI, KRISHNAN M., HESS, DAVID C. · 2023 to 2025
$1.8M
Duke Testing Site for Stroke Preclinical Assessment NetworkU01NS130598 · NINDS · DUKE UNIVERSITY · PI SHENG, HUAXIN, YANG, WEI · 2023 to 2025
$1.7M
Novel anti-NPC aggregation strategy against brain ischemia-reperfusion injuryR01NS097875 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI HU, BINGREN · 2017 to 2021
$1.7M
The Role of Lysosomal Membrane Permeabilization and Cathepsin B Release in Stroke Brain InjuryR01NS129553 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bingren Hu · 2023 to 2026
$1.5M
The University of Iowa Stroke Preclinical Assessment Center for Neuroprotection in strokeU01NS113388 · NINDS · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR, LEIRA, ENRIQUE CARLOS · 2019 to 2021
$1.1M
USC Neurosurgery Research and Education Training ProgramUE5NS099008 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William J Mack · 2024 to 2026
$126k
BLRD VA I01 BX001696BLRD VA I01 BX005814NINDS NIH HHS R01 NS097875NINDS NIH HHS R01 NS129553NINDS NIH HHS R01 NS134895NINDS NIH HHS U01 NS113388NINDS NIH HHS U01 NS130557NINDS NIH HHS U01 NS130585NINDS NIH HHS U01 NS130588NINDS NIH HHS U01 NS130590NINDS NIH HHS U01 NS130598NINDS NIH HHS U24 NS113452NINDS NIH HHS U24 NS130600NINDS NIH HHS UE5 NS099008
6 · The paper itself

Abstract

Current translational rodent stroke models induce middle cerebral artery occlusion (MCAo) using nylon filaments, injected emboli, intraluminal thrombin, or perivascular endothelin-1 to simulate human stroke. Among these methods, thromboemboli injection followed by thrombolysis best mimics the neuroinflammatory events seen in human patients and may be preferable to the inert nylon filament method most widely used. The standard thromboembolic models, used in leading single laboratories, however, can be time-consuming, produce variable results, and require considerable skill to master. To address these limitations, we developed a thromboembolic MCAo model that targets vessel occlusion and uses intravenous thrombolysis to achieve recanalization, paralleling the systemic thrombolysis administered in clinical scenarios. To reduce the number of animals, we developed a method to store blood from donor animals for later emboli preparation for multiple subjects. Our utilization of prefabricated Doccol microcatheters simplifies thrombus preparation and injection by pre-loading thromboemboli into the microcatheters that are then inserted into the internal carotid artery. To achieve recanalization, we infused intravenous Tenecteplase at a dose of 1.5 mg/kg. To promote reproducibility, we prepared and field-tested standard operating procedures, training videos, and hands-on surgical training workshops. The model uses a standard surgical approach that should be familiar to all investigators who use the widely accepted nylon filament model. Passage of the microcatheter into the distal internal carotid artery, avoiding the pterygopalatine artery, is accomplished in a manner similar to the nylon filament insertion. Recovery and post-stroke assessments may be done with typical behavioral, radiographic, and histologic protocols. This model offers a practical, reproducible, and accessible approach for investigators seeking a thromboembolic MCAo model with controlled recanalization.

Indexed as

Disease Models, AnimalInfarction, Middle Cerebral ArteryStrokeThromboembolismThrombolytic TherapyAnimalsFibrinolytic AgentsMaleRatsTissue Plasminogen ActivatorFibrinolytic AgentsTissue Plasminogen Activator

Identifiers

PMID41490186
PMCPMC13326433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.